Mainz Biomed B.V.
NASDAQ:MYNZ
2.55 (USD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.521 | 0.215 | 0.5 | 0.251 | 0.278 | 0.16 | 0.417 | 0.247 | 0.247 | 0.07 | 0.07 |
| Cost of Revenue
| 0.202 | 0.175 | 0.222 | 0.218 | 0.13 | 0.335 | 0.065 | 0.185 | 0.185 | 0.086 | 0.086 |
| Gross Profit
| 0.319 | 0.04 | 0.278 | 0.033 | 0.149 | -0.175 | 0.353 | 0.062 | 0.062 | -0.015 | -0.015 |
| Gross Profit Ratio
| 0.613 | 0.187 | 0.556 | 0.133 | 0.534 | -1.093 | 0.845 | 0.249 | 0.249 | -0.218 | -0.218 |
| Reseach & Development Expenses
| 3.243 | 1.999 | 5.25 | 2.964 | 0.696 | 0.261 | 0.206 | 0.156 | 0.156 | 0.063 | 0.063 |
| General & Administrative Expenses
| 4.523 | 3.531 | 4.816 | 7.371 | 10.461 | 8.227 | 0.251 | 0.229 | 0.229 | 0.143 | 0.143 |
| Selling & Marketing Expenses
| 2.361 | 1.248 | 3.124 | 2.096 | 2.882 | 0.807 | 0.15 | 0.055 | 0.055 | 0.045 | 0.045 |
| SG&A
| 6.884 | 4.486 | 7.94 | 9.467 | 13.343 | 9.035 | 0.241 | 0.284 | 0.284 | 0.188 | 0.188 |
| Other Expenses
| 0 | 0 | 0.063 | -0.226 | 0.112 | 0.011 | 0.011 | 0.015 | 0.015 | 0.004 | 0.004 |
| Operating Expenses
| 10.126 | 6.486 | 13.253 | 12.452 | 13.905 | 11.083 | 0.241 | 0.456 | 0.456 | 0.254 | 0.254 |
| Operating Income
| -9.807 | -6.59 | -12.975 | -12.279 | -13.896 | -9.47 | -0.241 | -0.178 | -0.178 | -0.188 | -0.188 |
| Operating Income Ratio
| -18.832 | -30.687 | -25.939 | -48.843 | -49.899 | -59.174 | -0.577 | -0.722 | -0.722 | -2.671 | -2.671 |
| Total Other Income Expenses Net
| -1.216 | 1.407 | -0.147 | 0.038 | 0.018 | -1.958 | -0 | -0.115 | -0.115 | -0.051 | -0.051 |
| Income Before Tax
| -11.024 | -5.183 | -13.122 | -12.51 | -13.877 | -11.428 | -0.241 | -0.293 | -0.293 | -0.239 | -0.239 |
| Income Before Tax Ratio
| -21.168 | -24.135 | -26.233 | -49.762 | -49.833 | -71.411 | -0.577 | -1.189 | -1.189 | -3.401 | -3.401 |
| Income Tax Expense
| 0 | 0 | 0.147 | -0.213 | 0.279 | 0.085 | -0.494 | 0.019 | 0.019 | -0.001 | -0.001 |
| Net Income
| -11.024 | -5.183 | -13.269 | -12.575 | -13.877 | -11.428 | -0.241 | -0.293 | -0.293 | -0.239 | -0.239 |
| Net Income Ratio
| -21.168 | -24.135 | -26.526 | -50.022 | -49.833 | -71.411 | -0.577 | -1.189 | -1.189 | -3.401 | -3.401 |
| EPS
| -19.73 | -11.73 | -0.9 | -0.87 | -1 | -1.3 | -0.02 | -0.025 | -0.025 | -0.02 | -0.02 |
| EPS Diluted
| -19.73 | -11.73 | -0.9 | -0.89 | -0.98 | -1.3 | -0.02 | -0.025 | -0.025 | -0.02 | -0.02 |
| EBITDA
| -9.471 | -4.694 | -12.4 | -11.877 | -13.841 | -9.498 | -0.22 | -0.146 | -0.146 | -0.184 | -0.184 |
| EBITDA Ratio
| -18.187 | -21.856 | -24.791 | -47.246 | -49.701 | -59.35 | -0.527 | -0.592 | -0.592 | -2.61 | -2.61 |